One in five children diagnosed with celiac disease in a new study had a form that standard biopsies routinely miss. Published June 30 in the European Journal of Pediatrics, the research adds to growing evidence that doctors need to biopsy a specific part of the small intestine separately—or some celiac kids will leave endoscopy without a diagnosis.
The form is called ultra-short celiac disease (USCD). Unlike standard celiac, where damage spreads through much of the small intestine, USCD damage is confined to the duodenal bulb—the very first centimeter or two just past the stomach. Standard biopsy protocol focuses further down. If doctors skip the bulb, USCD goes undetected.
What This Means for You
This study followed 78 children with confirmed celiac disease and found that 16 of them—about 20%—had USCD. Every one of those children was diagnosed only because their doctors took a separate biopsy from the duodenal bulb. Without that extra step, those kids would have left the procedure with a clean result and no celiac diagnosis.
Two things make USCD especially hard to catch. First, children with USCD had much lower levels on the standard celiac blood test—the tTG-IgA. The USCD group registered a median of 22.50 IU/L compared to 162.00 IU/L in children with standard celiac. Low scores can be interpreted as “not severe enough to worry about,” but this study shows that reading is wrong. Lower numbers here reflect limited geographic damage, not limited harm.
Second, 87.5% of children with USCD had none of the classic digestive symptoms—no chronic diarrhea, no bloating, no obvious malabsorption. These children were sick, but not in the way most doctors expect. Without clear symptoms and without high antibody levels, they are easy to overlook at every stage of evaluation.
For celiac parents, this is clarifying and uncomfortable at the same time. It means getting a diagnosis is not just about passing a blood test threshold. It means making sure the gastroenterologist performing the endoscopy knows to biopsy the duodenal bulb separately—and that those samples go into a separate container so pathologists can read them independently.
Key Takeaways
- About 1 in 5 children in this study had ultra-short celiac disease, a form confined to the very start of the small intestine.
- Standard biopsies taken further down the small intestine miss USCD entirely—a separate bulb biopsy is required.
- Children with USCD had tTG-IgA blood levels roughly seven times lower than children with classic celiac, which can falsely suggest celiac is unlikely.
- Nearly 9 in 10 USCD children had no classic digestive symptoms, making them harder to identify at every stage.
- Before any endoscopy for suspected celiac, ask whether the gastroenterologist will biopsy the duodenal bulb separately and label those samples independently.
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
Ultra-Short vs. Classic Celiac: Where the Damage Sits
In classic celiac disease, gluten triggers an immune reaction that damages the villi—tiny finger-like projections lining the small intestine that absorb nutrients. This damage is called villous atrophy, and it typically spreads across the distal duodenum (the lower portion of the intestine’s first section) and beyond.
In ultra-short celiac disease, the same villous atrophy occurs, but it stays confined to the duodenal bulb—the very first few centimeters of the duodenum, directly below the stomach. Further down, the tissue looks entirely normal.
Standard endoscopy biopsy protocol for celiac disease targets the distal duodenum. Some guidelines recommend additional biopsies from the bulb, but the practice is not universal. When a doctor collects samples from multiple sites and places them into a single container, pathologists cannot tell which tissue came from where. USCD damage in the bulb then disappears into a pool of normal-looking tissue from further down, and the result reads negative.
Why Low tTG-IgA Throws Off the Diagnosis
Tissue transglutaminase IgA (tTG-IgA) is the standard blood test used to screen for celiac disease. It detects an antibody the immune system produces in response to gluten-driven intestinal damage. Higher levels generally correlate with more widespread injury.
Because USCD damage is limited to a small area, tTG-IgA levels come back lower than in classic celiac. In this study, USCD patients had a median tTG-IgA of 22.50 IU/L versus 162.00 IU/L in children with standard celiac—roughly seven times lower. A physician who sees a borderline or low tTG-IgA may conclude celiac is unlikely, or that something else is driving the symptoms. The blood test is not wrong; it is measuring less damage because the damage covers less territory, not because the disease is absent.
Atypical Presentations Compound the Problem
Classic celiac disease often presents with malabsorption symptoms: chronic diarrhea, steatorrhea (fatty, greasy stools), poor weight gain, and abdominal distension. These are the red flags most physicians associate with celiac and that typically prompt a gastroenterology referral.
USCD looked different in this cohort. Nearly 90% of those patients had isolated symptoms outside the digestive system—iron-deficiency anemia, short stature for age, or elevated liver enzymes—without the gastrointestinal complaints that usually trigger a celiac workup. A child presenting with anemia alone may not be referred for an endoscopy at all, especially when the tTG-IgA comes back low.
Separate Containers, Separate Answers
The research team enrolled patients between February 2024 and March 2026 at Gaziantep City Hospital in Turkey. Their protocol was specific: biopsy specimens from the duodenal bulb and the distal duodenum were placed in separate containers so pathologists could evaluate each site independently.
That detail matters. Celiac disease can be patchy—meaning not every centimeter of tissue looks the same within the same patient. Pooling samples from multiple sites obscures this variability. The study’s approach is a practical fix that any pediatric endoscopy unit could adopt without new equipment.
Building on earlier findings described in High Prevalence of Ultra-Short Celiac Disease in Children with Low tTG-IgA Levels, this study adds real-world frequency data from a clinical setting: USCD is not rare. It represented roughly 1 in 5 of diagnosed celiac children at this center—and those are only the children who happened to receive bulb biopsies in the first place.
What Needs to Change
The findings from Sahin, Uzger, and Goktepe point to a straightforward protocol adjustment: take separate biopsies from the duodenal bulb, place them in a labeled, separate container, and evaluate them independently. No new technology required. No experimental techniques.
For celiac families, the practical question is short and worth asking before any endoscopy: will the gastroenterologist biopsy the duodenal bulb separately, and will those samples be processed and read on their own? That one question could be the difference between a diagnosis and years of unexplained symptoms.
Related Coverage
References
Sahin Y, Uzger A, Goktepe AR. The frequency and characteristics of ultra-short celiac disease in children: A single-center experience. Eur J Pediatr. 2026 Jun 30;185(7):541. doi: 10.1007/s00431-026-07209-6